title: Ataxia telangiectasia: a review.
abstract: Ataxia telangiectasia (A-T) is an autosomal recessive disorder primarily characterized by cerebellar degeneration, telangiectasia, immunodeficiency, cancer susceptibility and radiation sensitivity. A-T is often referred to as a genome instability or DNA damage response syndrome.
  
  
  
  The world-wide prevalence of A-T is estimated to be between 1 in 40,000 and 1 in 100,000 live births.
  
  
  
  A-T is a complex disorder with substantial variability in the severity of features between affected individuals, and at different ages. Neurological symptoms most often first appear in early childhood when children begin to sit or walk. They have immunological abnormalities including immunoglobulin and antibody deficiencies and lymphopenia. People with A-T have an increased predisposition for cancers, particularly of lymphoid origin. Pulmonary disease and problems with feeding, swallowing and nutrition are common, and there also may be dermatological and endocrine manifestations.
  
  
  
  A-T is caused by mutations in the ATM (Ataxia Telangiectasia, Mutated) gene which encodes a protein of the same name. The primary role of the ATM protein is coordination of cellular signaling pathways in response to DNA double strand breaks, oxidative stress and other genotoxic stress.
  
  
  
  The diagnosis of A-T is usually suspected by the combination of neurologic clinical features (ataxia, abnormal control of eye movement, and postural instability) with one or more of the following which may vary in their appearance: telangiectasia, frequent sinopulmonary infections and specific laboratory abnormalities (e.g. IgA deficiency, lymphopenia especially affecting T lymphocytes and increased alpha-fetoprotein levels). Because certain neurological features may arise later, a diagnosis of A-T should be carefully considered for any ataxic child with an otherwise elusive diagnosis. A diagnosis of A-T can be confirmed by the finding of an absence or deficiency of the ATM protein or its kinase activity in cultured cell lines, and/or identification of the pathological mutations in the ATM gene.
  
  
  
  There are several other neurologic and rare disorders that physicians must consider when diagnosing A-T and that can be confused with A-T. Differentiation of these various disorders is often possible with clinical features and selected laboratory tests, including gene sequencing.
  
  
  
  Antenatal diagnosis can be performed if the pathological ATM mutations in that family have been identified in an affected child. In the absence of identifying mutations, antenatal diagnosis can be made by haplotype analysis if an unambiguous diagnosis of the affected child has been made through clinical and laboratory findings and/or ATM protein analysis.
  
  
  
  Genetic counseling can help family members of a patient with A-T understand when genetic testing for A-T is feasible, and how the test results should be interpreted.
  
  
  
  Treatment of the neurologic problems associated with A-T is symptomatic and supportive, as there are no treatments known to slow or stop the neurodegeneration. However, other manifestations of A-T, e.g. immunodeficiency, pulmonary disease, failure to thrive and diabetes can be treated effectively.
authors.affiliation: A-T Children's Project, Coconut Creek, Florida, USA. cynthia@atcp.org.
authors.forename: Cynthia
authors.identifier: 0000-0003-1442-2514
authors.initials: C
authors.lastname: Rothblum-Oviatt
authors.affiliation: The Ataxia Telangiectasia Clinical Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Wright
authors.affiliation: The Ataxia Telangiectasia Clinical Center, Departments of Pediatrics and Pediatric Respiratory Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
authors.forename: Maureen A
authors.initials: MA
authors.lastname: Lefton-Greif
authors.affiliation: The Ataxia Telangiectasia Clinical Center, Departments of Pediatrics and Pediatric Respiratory Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
authors.forename: Sharon A
authors.initials: SA
authors.lastname: McGrath-Morrow
authors.affiliation: The Ataxia Telangiectasia Clinical Center, Departments of Pediatrics and Neurology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
authors.forename: Thomas O
authors.initials: TO
authors.lastname: Crawford
authors.affiliation: The Ataxia Telangiectasia Clinical Center, Departments of Pediatrics, Medicine and Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
authors.forename: Howard M
authors.initials: HM
authors.lastname: Lederman
mesh_terms: D000818:Animals; D001260:Ataxia Telangiectasia / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D002531:Cerebellum / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008171:Lung Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D009154:Mutation / Q000235:genetics; D011689:Purkinje Cells / Q000378:metabolism
keywords: Cancer; Cerebellum; Dysphagia; Immunodeficiency; Neurodegeneration; Pulmonary disease; Purkinje cells